Biofrontera Q1 revenue up 17% to $10.1M; gross margin 80%; PDUFA for sBCC set Sept 2026

Biofrontera Inc.

Revenue $10.1M (+17% YoY); gross margin 80% (vs 62% Q1 2025) from new earnout structure.
Net loss $4.8M ($0.41/shr) vs $4.2M ($0.47/shr); operating loss improved to $4.3M from $4.5M.
Adjusted EBITDA -$3.6M vs -$4.4M; cash consumption near zero; cash $6.3M vs $1.8M Q1 2025.
FDA accepted sNDA for Ameluz PDT for superficial BCC; PDUFA target date Sept 28, 2026.
Positive Phase 3 AK results (primary endpoint met) and Phase 2b acne data (58% lesion reduction); regained Nasdaq compliance.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Biofrontera Inc. reported first quarter of 2026 results: revenue $10.1 million, net income $4.8 million, or $0.41 per share, EPS $0.41 per share.

Period: first quarter of 2026
Revenue: $10.1 million
Net income: $4.8 million, or $0.41 per share
EPS: $0.41 per share
Result: reported results

Exact text from the filing

today reported financial results for the three months ended March 31, 2026 and provided a business update. First Quarter Financial Highlights ● Revenues for Q1 2026 were $10.1 million, a ~17% increase compared to $8.6 million for the same period in 2025. ● Gross margins were about 80%, an 18 percentage points increase compared to approximately 62% in Q1

View on SEC.gov

Browse all earnings releases →

Biofrontera Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-022875

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.